- A 24-wk regimen of daclatasvir (DCV; Daklinza) + sofosbuvir (SOF; Sovaldi) with ribavirin (RBV) achieves a high HCV-1 clearance rate in treatment-experienced patients with decompensated cirrhosis.
Why this matters
- This population is typically excluded from clinical trials.
You’ve reached the visitor articles limit
reserved for healthcare professionals
Register to read more
Already have an account? Login now